Contributors |
|
xvii | |
Editor biography |
|
xxi | |
Preface |
|
xxiii | |
Acknowledgments |
|
xxv | |
Special acknowledgment |
|
xxvii | |
|
1 Exosome basic mechanisms |
|
|
|
|
|
|
|
1 Exosomes biogenesis and release |
|
|
1 | (1) |
|
2 Endosomal sorting complex request for transport (ESCRT) and its role in exosome biogenesis |
|
|
2 | (2) |
|
3 ESCRT-independent mechanism of exosomes biogenesis |
|
|
4 | (2) |
|
4 MVBs transport to the membrane and exosomes release |
|
|
6 | (1) |
|
5 Basal composition and cargo |
|
|
7 | (5) |
|
|
12 | (11) |
|
6.1 Exosome mechanism of action |
|
|
12 | (5) |
|
|
17 | (4) |
|
|
21 | (2) |
|
2 Methods for exosome isolation and characterization |
|
|
|
|
|
|
|
|
|
23 | (1) |
|
2 Methods for exosome isolation |
|
|
24 | (4) |
|
2.1 Differential centrifugation |
|
|
24 | (1) |
|
2.2 Filtration and ultracentrifugation |
|
|
24 | (1) |
|
2.3 Density gradient centrifugation |
|
|
25 | (1) |
|
|
25 | (1) |
|
2.5 Immunoaffinity capture-based isolation |
|
|
26 | (1) |
|
2.6 Summary of methods for exosome isolation |
|
|
27 | (1) |
|
3 Methods for exosome characterization |
|
|
28 | (5) |
|
3.1 Ultrastructural analysis |
|
|
28 | (1) |
|
|
29 | (1) |
|
|
30 | (1) |
|
|
31 | (1) |
|
|
32 | (1) |
|
3.6 ExoView characterization platform |
|
|
32 | (1) |
|
3.7 In vivo exosome tracking |
|
|
32 | (1) |
|
|
33 | (2) |
|
|
33 | (1) |
|
4.2 Exosomal microRNA (miRNA; miR) |
|
|
34 | (1) |
|
|
35 | (4) |
|
|
35 | (4) |
|
3 Exosomes, microvesicles, and their friends in solid tumors |
|
|
|
|
|
|
39 | (2) |
|
2 Cellular uptake of (cancer) cell-derived EVs |
|
|
41 | (5) |
|
2.1 Positioning role of early and late endosomes in nuclear transfer of extracellular information |
|
|
44 | (1) |
|
|
45 | (1) |
|
3 EVs and cancer microenvironment |
|
|
46 | (9) |
|
3.1 Role of EVs in metastasis |
|
|
46 | (5) |
|
3.2 Cancer cell-derived EVs and inhibition of the anti-cancer immune response |
|
|
51 | (1) |
|
3.3 EVs, angiogenesis, endothelial cells, and platelets |
|
|
52 | (1) |
|
3.4 EVs and cancer drug resistance |
|
|
53 | (2) |
|
4 Environmental clues and carcinogenicity of anticancer drugs---Impact on EVs |
|
|
55 | (1) |
|
|
55 | (1) |
|
4.2 Carcinogenic potential of anticancer drugs and treatments |
|
|
56 | (1) |
|
5 Clinical applications of EVs |
|
|
56 | (10) |
|
5.1 Liquid biopsy: Cancer cell-derived EV-associated proteins and nucleic acids as biomarkers |
|
|
57 | (3) |
|
5.2 EV-based anti-cancer strategies |
|
|
60 | (6) |
|
6 EV-based clinical cancer therapy studies |
|
|
66 | (1) |
|
7 Conclusion and perspective |
|
|
67 | (14) |
|
|
67 | (1) |
|
|
67 | (14) |
|
4 Hematologic malignancies: The exosome contribution in tumor progression |
|
|
|
|
|
|
1 Introduction: Hematologic malignancies and the tumor microenvironment |
|
|
81 | (1) |
|
2 Physiological regulation and pathological alterations of hematopoiesis by extracellular vesicles |
|
|
82 | (2) |
|
3 Endothelial remodeling by extracellular vesicles |
|
|
84 | (1) |
|
4 Extracellular vesicles reprogram the bone marrow stromal cells |
|
|
85 | (1) |
|
5 Extracellular vesicles alter bone homeostasis |
|
|
86 | (2) |
|
6 Extracellular vesicles regulate immune cell functions |
|
|
88 | (5) |
|
6.1 Exosomes and NK cells |
|
|
90 | (1) |
|
6.2 Exosomes and CD8+cytotoxic lymphocytes |
|
|
91 | (1) |
|
|
91 | (1) |
|
|
92 | (1) |
|
6.5 Exosomes and monocytes |
|
|
92 | (1) |
|
|
93 | (1) |
|
7 Extracellular vesicles mediate drug resistance |
|
|
93 | (1) |
|
8 Clinical relevance of exosome for disease diagnosis and drug therapy monitoring |
|
|
94 | (1) |
|
|
95 | (6) |
|
|
95 | (1) |
|
|
95 | (1) |
|
|
96 | (5) |
|
5 Physiological and pathological functions of prostasomes: From basic research to clinical application |
|
|
|
|
|
|
|
|
|
101 | (1) |
|
2 Prostasomes derived from normal prostatic epithelial cells |
|
|
102 | (2) |
|
3 Physiological contribution of prostasomes |
|
|
104 | (3) |
|
3.1 Sperm motility and prostasomes |
|
|
104 | (1) |
|
3.2 Immunosuppressive activity of prostasomes |
|
|
105 | (1) |
|
3.3 Antioxidant capacity of prostasomes |
|
|
105 | (1) |
|
3.4 Antibacterial activity of prostasomes |
|
|
106 | (1) |
|
3.5 Capacitation and acrosome reaction and prostasomes |
|
|
106 | (1) |
|
4 Prostasomes derived from prostate cancer |
|
|
107 | (2) |
|
5 Pathological contribution of prostasomes in prostate cancer |
|
|
109 | (1) |
|
6 Clinical application of prostasomes for prostate cancer treatment |
|
|
110 | (6) |
|
6.1 Strategy for prostate cancer treatment targeting prostasomes |
|
|
110 | (2) |
|
6.2 Prostasome-associated prostate cancer biomarker |
|
|
112 | (4) |
|
|
116 | (7) |
|
|
116 | (1) |
|
|
117 | (1) |
|
|
117 | (6) |
|
6 The function and therapeutic use of exosomes in bacterial infections |
|
|
|
|
|
|
123 | (2) |
|
|
125 | (1) |
|
|
125 | (2) |
|
|
126 | (1) |
|
4 Extracellular vesicles, pathogens and infectious diseases |
|
|
127 | (1) |
|
5 Composition and function of exosomes and EVs during mycobacterial infections |
|
|
128 | (4) |
|
5.1 M.tb infection and characterization of exosome and EV cargo |
|
|
130 | (1) |
|
5.2 Modulating of the adaptive immune response by EVs during a mycobacterial infection |
|
|
131 | (1) |
|
6 Composition and function of exosomes and EVs during other bacterial infections |
|
|
132 | (3) |
|
7 EVs as vaccines against bacterial infections |
|
|
135 | (1) |
|
8 EVs as a drug delivery system |
|
|
136 | (2) |
|
9 Exosomes as a source of diagnostic biomarkers for infectious diseases |
|
|
138 | (1) |
|
|
139 | (8) |
|
|
140 | (7) |
|
7 Emerging therapeutic roles of exosomes in HIV-1 infection |
|
|
|
|
|
|
147 | (1) |
|
2 Exosomes and HIV-1: The chicken or egg? |
|
|
148 | (1) |
|
3 Exosomes as double-edged sword in HIV-1 |
|
|
149 | (3) |
|
|
152 | (1) |
|
5 Exosomes as biomarkers for HIV-1 |
|
|
153 | (3) |
|
6 Therapeutic potential of targeting exosomes |
|
|
156 | (6) |
|
6.1 Targeting viral proteins |
|
|
156 | (3) |
|
|
159 | (3) |
|
|
162 | (6) |
|
7.1 Understanding exosomal pathway in revising therapeutic strategy against viruses |
|
|
162 | (1) |
|
7.2 Advancement of technologies in exosome detection and characterization |
|
|
163 | (2) |
|
7.3 Key challenges of clinical application of exosomes |
|
|
165 | (2) |
|
7.4 Enhancement of exosomal therapeutic efficacy |
|
|
167 | (1) |
|
|
168 | (1) |
|
|
168 | (11) |
|
|
169 | (10) |
|
8 Extracellular vesicles in parasitic disease |
|
|
|
|
Andre Cronemberger-Andrade |
|
|
|
1 Extracellular vesicles and parasite |
|
|
179 | (1) |
|
|
180 | (3) |
|
|
183 | (3) |
|
|
186 | (1) |
|
|
187 | (2) |
|
|
189 | (1) |
|
|
190 | (1) |
|
|
191 | (8) |
|
|
193 | (6) |
|
9 Exosomes as intercellular communication messengers for cardiovascular and cerebrovascular diseases |
|
|
|
|
|
|
|
|
|
|
199 | (1) |
|
2 Exosomes biogenesis and release |
|
|
200 | (5) |
|
2.1 Cardiomyocytes-derived exosomes |
|
|
201 | (1) |
|
2.2 Endothelial cell-derived exosomes |
|
|
202 | (1) |
|
2.3 Mesenchymal stem/stromal cells derived exosomes |
|
|
202 | (1) |
|
2.4 Platelet-derived exosomes |
|
|
203 | (1) |
|
2.5 Leukocyte-derived exosomes |
|
|
203 | (1) |
|
2.6 Erythrocytes-derived exosomes |
|
|
204 | (1) |
|
2.7 Vascular smooth muscle cells derived exosomes |
|
|
204 | (1) |
|
2.8 Brain cells derived exosomes |
|
|
205 | (1) |
|
3 Exosomes characterization and methods of study and analysis |
|
|
205 | (3) |
|
|
205 | (1) |
|
|
206 | (1) |
|
|
207 | (1) |
|
4 Exosomes and coronary artery disease |
|
|
208 | (1) |
|
4.1 Exosomes as biomarkers in coronary artery disease |
|
|
208 | (1) |
|
4.2 Exosomes in the recovery after coronary artery disease |
|
|
209 | (1) |
|
5 Exosomes in myocardial ischemia and infarction |
|
|
209 | (3) |
|
5.1 Exosomes as biomarkers in myocardial ischemia/infarction |
|
|
209 | (1) |
|
5.2 Exosomes in the recovery after myocardial ischemia/infarction |
|
|
210 | (2) |
|
6 Exosomes in heart failure |
|
|
212 | (5) |
|
6.1 Exosomes as biomarkers in heart failure |
|
|
212 | (4) |
|
6.2 Exosomes in the recovery after heart failure |
|
|
216 | (1) |
|
7 Exosome in cardiac hypertrophy |
|
|
217 | (1) |
|
7.1 Exosomes as biomarkers in cardiac hypertrophy |
|
|
217 | (1) |
|
7.2 Exosomes in the recovery after cardiac hypertrophy |
|
|
218 | (1) |
|
8 Exosome in cardiac arrhythmia |
|
|
218 | (1) |
|
8.1 Exosomes as biomarkers in arrhythmia |
|
|
218 | (1) |
|
8.2 Exosomes in the recovery after arrhythmia |
|
|
219 | (1) |
|
9 Exosome in cerebrovascular diseases |
|
|
219 | (4) |
|
9.1 Exosomes as biomarkers in cerebrovascular diseases |
|
|
219 | (2) |
|
9.2 Exosomes as cargo in the brain |
|
|
221 | (1) |
|
9.3 Exosomes in the treatment of cerebrovascular diseases |
|
|
222 | (1) |
|
10 Concluding observations |
|
|
223 | (16) |
|
|
224 | (1) |
|
Competing financial interests |
|
|
224 | (1) |
|
|
224 | (15) |
|
10 Exosomes in cutaneous biology and dermatologic disease |
|
|
|
|
|
|
1 Keratinocytes, the major cells of the upper skin, secrete exosomes that modulate pigment production by melanocytes |
|
|
239 | (3) |
|
2 Keratinocyte and immune system exosomes modulate fibroblast expression of proteins that modify the extracellular matrix |
|
|
242 | (1) |
|
3 Keratinocyte exosomes modulate the immune system |
|
|
243 | (1) |
|
4 The dermis fibroblasts, specifically the dermal papilla cells, secrete exosomes that stimulate hair follicle growth phase, known as the anagen phase |
|
|
244 | (1) |
|
5 Disorders of fibrosis have dysregulated expression of fibroblasts exosomes |
|
|
245 | (1) |
|
6 Mast cell exosomes, containing phospholipase activity, stimulate Langerhans cell presentation of lipid antigens to T cells |
|
|
245 | (2) |
|
7 Exosomes in the fluid of bullous pemphigoid patients potentiates pathogenic inflammation |
|
|
247 | (1) |
|
|
247 | (4) |
|
8.1 Stem cell exosomes stimulate skin repair |
|
|
247 | (4) |
|
9 Intercellular adhesion molecules associated with exosomes, such as desmogleins, secreted from malignant cells can modulate the extracellular environment to promote tumor progression |
|
|
251 | (1) |
|
10 Exosomes are critical in the pathogenesis of malignant melanoma |
|
|
251 | (1) |
|
11 Exosomes in the circulation signal presence of metastatic squamous cell carcinomas, especially in recessive dystrophic epidermolysis bullosa patients |
|
|
252 | (1) |
|
12 Exosomes in circulation of patients with melanoma signal metastases and worsened prognosis |
|
|
253 | (1) |
|
|
254 | (3) |
|
|
254 | (3) |
|
11 Exosomes in nephrology |
|
|
|
|
|
|
|
257 | (1) |
|
|
257 | (1) |
|
1.2 Exosomes in the kidney and urinary tract: Special considerations |
|
|
257 | (1) |
|
1.3 A word on nomenclature |
|
|
258 | (1) |
|
|
258 | (4) |
|
|
258 | (2) |
|
2.2 Cellular origin and molecular cargo of urinary exosomes |
|
|
260 | (1) |
|
2.3 Uptake of EVs by kidney cells |
|
|
260 | (2) |
|
3 Urinary exosomes as biomarkers |
|
|
262 | (5) |
|
3.1 Two broad approaches to biomarker research |
|
|
262 | (1) |
|
3.2 Mechanistic biomarkers reporting on renal tubular function |
|
|
263 | (2) |
|
3.3 Biomarkers of renal disease |
|
|
265 | (2) |
|
4 Functional role of exosomes in the kidney and urinary tract |
|
|
267 | (6) |
|
4.1 Exosome signalling regulating tubulointerstitial cells |
|
|
267 | (6) |
|
4.2 Exosome-mediated interactions with urinary pathogens |
|
|
273 | (1) |
|
5 Potential for exosome-based therapies |
|
|
273 | (1) |
|
|
274 | (11) |
|
|
276 | (9) |
|
12 Extracellular vesicles in neurodegenerative disorders |
|
|
|
|
|
|
|
|
|
285 | (3) |
|
2 EV-mediated healthy CNS maintenance |
|
|
288 | (1) |
|
3 EVs in neurodegenerative diseases |
|
|
289 | (9) |
|
|
289 | (2) |
|
|
291 | (1) |
|
|
292 | (3) |
|
3.4 Amyotrophic lateral sclerosis |
|
|
295 | (1) |
|
3.5 Prion diseases (transmissible spongiform encephalopathies) |
|
|
296 | (2) |
|
4 Summary and conclusions |
|
|
298 | (9) |
|
|
298 | (9) |
|
13 Extracellular vesicles in fibrotic diseases: New applications for fibrosis diagnosis and treatment |
|
|
|
|
|
|
|
|
|
|
307 | (1) |
|
|
308 | (1) |
|
3 The involvement of EVs in pathogenesis of organ fibrosis |
|
|
309 | (5) |
|
3.1 EVs and hepatic fibrosis |
|
|
309 | (3) |
|
3.2 EVs and pulmonary fibrosis |
|
|
312 | (1) |
|
3.3 EVs and cardiac fibrosis and hypertrophy |
|
|
313 | (1) |
|
4 The involvement of EVs in fibrotic disease diagnosis |
|
|
314 | (2) |
|
4.1 EV-based biomarker in liver fibrosis |
|
|
314 | (1) |
|
4.2 EV-based biomarkers in pulmonary fibrosis |
|
|
315 | (1) |
|
4.3 Current limitations of EVs analysis in disease diagnosis |
|
|
316 | (1) |
|
5 EVs as new applications for fibrosis treatment |
|
|
316 | (3) |
|
5.1 Reversibility of organ fibrosis |
|
|
316 | (1) |
|
5.2 The roles of EVs as new applications for fibrosis treatment |
|
|
317 | (1) |
|
5.3 Mesenchymal stem cell-derived EVs |
|
|
317 | (1) |
|
5.4 Body fluid-derived EVs |
|
|
318 | (1) |
|
5.5 Current limitations of EV-based therapy |
|
|
319 | (1) |
|
6 Conclusions and perspectives |
|
|
319 | (6) |
|
|
319 | (1) |
|
|
319 | (6) |
|
14 Mechanisms of exosome-mediated immune cell crosstalk in inflammation and disease |
|
|
|
|
|
|
1 Transfer of exosomes during immune cell-interactions participate in the inflammatory response |
|
|
325 | (2) |
|
2 Relevance of exosome biogenesis and secretion pathways in health and disease |
|
|
327 | (1) |
|
3 Mechanisms of exosome release in vivo in disease |
|
|
328 | (1) |
|
4 Exosomes and immune checkpoint inhibition in oncology |
|
|
329 | (1) |
|
5 Exosomes in trauma and ischemia/reperfusion injury |
|
|
329 | (2) |
|
6 Exosomes and inflammatory bowel disease |
|
|
331 | (1) |
|
7 Exosomes and wound healing |
|
|
331 | (1) |
|
|
332 | (1) |
|
9 Potential for species-specific mechanisms of exosome release |
|
|
333 | (1) |
|
10 Exosomes and technology-driven advances |
|
|
333 | (1) |
|
|
334 | (9) |
|
|
335 | (8) |
|
15 Exosomes in metabolic syndrome |
|
|
|
|
Ramaroson Andriantsitohaina |
|
|
|
|
343 | (1) |
|
2 Different components of MetS |
|
|
344 | (2) |
|
|
344 | (1) |
|
|
345 | (1) |
|
2.3 Arterial hypertension |
|
|
345 | (1) |
|
|
345 | (1) |
|
3 EVs: Biomarkers of MetS components |
|
|
346 | (2) |
|
|
346 | (1) |
|
|
347 | (1) |
|
|
347 | (1) |
|
3.4 IR and type 2 diabetes mellitus (T2DM) |
|
|
348 | (1) |
|
3.5 All MetS components gathered |
|
|
348 | (1) |
|
4 EVs: Bioeffectors of the MetS |
|
|
348 | (4) |
|
4.1 Exosomes and metabolic complications of obesity: A role for fat-derived exosomes? |
|
|
348 | (2) |
|
4.2 Exosomes as promoters of endothelial dysfunction |
|
|
350 | (1) |
|
4.3 Role of exosomes in blood pressure regulation |
|
|
351 | (1) |
|
4.4 Exosomes as vectors promoting lipid disorders |
|
|
352 | (1) |
|
5 Exosomes as a new mode of communication between hosts and microbiota |
|
|
352 | (1) |
|
|
353 | (4) |
|
|
353 | (1) |
|
|
353 | (4) |
|
16 Potential role of exosomes in reproductive medicine and pregnancy |
|
|
|
|
|
|
357 | (1) |
|
2 Extracellular vesicles: Their diversity, biogenesis and secretion |
|
|
358 | (3) |
|
2.1 Exosomes: Intercellular interactions and functions |
|
|
358 | (3) |
|
3 The origin and functions of exosomes in pregnancy |
|
|
361 | (10) |
|
3.1 Exosomes from placenta |
|
|
361 | (3) |
|
3.2 Detection and isolation of placental exosomes |
|
|
364 | (1) |
|
3.3 Bio-distribution of placental exosomes and their effect on target cells |
|
|
365 | (6) |
|
4 Exosomes in complications of pregnancy |
|
|
371 | (3) |
|
4.1 Gestational diabetes mellitus (CDM) |
|
|
371 | (1) |
|
|
372 | (1) |
|
|
373 | (1) |
|
|
374 | (11) |
|
|
374 | (1) |
|
|
375 | (10) |
|
17 Exosomes in respiratory disease |
|
|
|
|
|
1 Exosome in lung microenvironment and pathogenesis |
|
|
385 | (2) |
|
2 The roles of exosomes derived from the effector immune cells and structural cells in lung microenvironment |
|
|
387 | (3) |
|
3 Exosomes in lung diseases |
|
|
390 | (12) |
|
|
390 | (3) |
|
|
393 | (5) |
|
|
398 | (1) |
|
|
399 | (2) |
|
|
401 | (1) |
|
3.6 Other respiratory diseases |
|
|
401 | (1) |
|
4 Clinical applications of exosomes in respiratory diseases: Clinical trials and future perspectives |
|
|
402 | (13) |
|
|
405 | (10) |
|
18 Exosomes in retinal diseases |
|
|
|
|
|
|
|
|
415 | (2) |
|
2 General disease mechanisms |
|
|
417 | (8) |
|
|
417 | (1) |
|
|
418 | (2) |
|
2.3 Inflammation and immune responses |
|
|
420 | (2) |
|
2.4 Retinal and choroidal angiogenesis |
|
|
422 | (2) |
|
|
424 | (1) |
|
3 Exosome-based therapeutic approaches |
|
|
425 | (1) |
|
|
425 | (8) |
|
|
426 | (7) |
|
19 MSC-exosomes in regenerative medicine |
|
|
|
|
|
|
|
|
433 | (1) |
|
2 Exosomes derived from mesenchymal stromal cells |
|
|
434 | (1) |
|
3 Application of MSC-EVs in regenerative medicine |
|
|
435 | (9) |
|
3.1 Neurological regeneration |
|
|
436 | (1) |
|
3.2 Cardiovascular regeneration |
|
|
437 | (2) |
|
|
439 | (1) |
|
|
440 | (1) |
|
3.5 Skeletal, chondral, and muscular regeneration |
|
|
441 | (1) |
|
3.6 Cutaneous regeneration |
|
|
442 | (2) |
|
4 Exosomal modification in regenerative medicine |
|
|
444 | (7) |
|
4.1 Engineering the exosomal surface |
|
|
444 | (1) |
|
4.2 Engineering effective exosome contents |
|
|
445 | (6) |
|
5 Clinical application of MSC-exosomes in regenerative medicine |
|
|
451 | (1) |
|
6 Limitations and challenges |
|
|
451 | (3) |
|
7 Conclusion and perspectives |
|
|
454 | (13) |
|
|
455 | (1) |
|
|
455 | (12) |
|
20 The potential of exosomes as theragnostics in various clinical situations |
|
|
|
|
1 Exosomes as biomarkers of diseases and therapeutic or vaccine candidates for infections |
|
|
467 | (6) |
|
2 Extracellular vesicles (EVs) as a drug delivery system |
|
|
473 | (14) |
|
|
480 | (7) |
|
21 Exosomes, gemmules, pangenesis and Darwin |
|
|
|
|
|
487 | (1) |
|
|
487 | (5) |
|
2.1 The origin of species |
|
|
487 | (2) |
|
|
489 | (2) |
|
2.3 The inheritance of acquired characteristics |
|
|
491 | (1) |
|
3 The neo-Darwinist (modern synthesis) view |
|
|
492 | (5) |
|
3.1 Early experiments to test inheritance of acquired characteristics |
|
|
492 | (2) |
|
3.2 Randomness of mutations |
|
|
494 | (1) |
|
3.3 Is the Weismann barrier now "embodied by the Central dogma of molecular biology"? |
|
|
494 | (1) |
|
3.4 Shifting definition of a gene |
|
|
495 | (2) |
|
|
497 | (1) |
|
5 Modern work on trans-generational role of exosomes and microRNAs |
|
|
498 | (5) |
|
|
499 | (1) |
|
|
499 | (4) |
Index |
|
503 | |